-
Wortmannin Workflows for PI3K Signaling in HCC
2026-09-05
Wortmannin is a practical PI3K inhibitor for testing whether PI3K/AKT activation drives ferroptosis resistance, apoptosis changes, or autophagy phenotypes. This workflow translates recent FAT4–PI3K/AKT findings into controlled cell-based experiments while addressing solubility, irreversible target engagement, and concentration-dependent kinase selectivity.
-
Coumestrol Workflows for ER and RA-FLS Research
2026-09-04
Coumestrol combines estrogen-receptor pharmacology with a practical model for studying ferroptosis, mitochondrial stress, and inflammatory signaling in rheumatoid arthritis fibroblast-like synoviocytes. This workflow-focused guide helps researchers separate receptor effects from concentration-dependent cytotoxicity while improving assay reproducibility.
-
Measuring Drug Response Beyond Cell Viability
2026-09-04
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly interchangeable measures capture different combinations of proliferative arrest and cell death. This framework encourages cancer researchers to use time-resolved, orthogonal assays rather than interpreting a single viability value as a complete drug-response phenotype.
-
Urolithin A: From Mitochondrial Quality to Fibrosis
2026-09-03
Urolithin A offers translational researchers a mechanistically distinctive way to study mitochondrial quality control, mitophagy, inflammation, and respiratory function. This article connects those questions with evidence from hepatic stellate cell metabolism while defining what is established, what remains hypothetical, and how to build a rigorous validation strategy.
-
3-Deazaneplanocin (DZNep) Research Workflows
2026-09-03
Build reproducible DZNep experiments for apoptosis induction in AML cells, hepatocellular carcinoma research, and cancer stem cell targeting. This guide combines epigenetic mechanism, subtype-aware assay design, practical dosing, and troubleshooting for stronger translational datasets.
-
Cy3 NHS ester (non-sulfonated) Workflow Guide
2026-09-02
Cy3 NHS ester (non-sulfonated), SKU A8100, provides amine-reactive orange fluorescence for labeling soluble proteins, peptides, oligonucleotides, and DNA. It is appropriate for workflows that can tolerate a DMSO or DMF co-solvent, but not for water-only labeling or delicate samples that are destabilized by organic solvent exposure.
-
Engage & Evasion Improves Extracellular Vesicle Therapy
2026-09-02
Liu et al. developed a sequential “Engage & Evasion” strategy in which low-CD47 extracellular vesicles first interact with and saturate the mononuclear phagocyte system, followed by CD47-high vesicles designed to resist uptake. The approach reduced liver and spleen entrapment, increased circulating vesicle levels, and improved accumulation outside major MPS organs, providing a distribution-focused framework for ischemic disease therapy.
-
ddATP Workflows for Controlled DNA Termination
2026-09-01
ddATP provides sequence-aware control over DNA synthesis, enabling more than conventional Sanger sequencing: it can distinguish polymerase-dependent replication, tune PCR termination, and probe repair-associated synthesis. This guide translates the mouse-oocyte break-induced replication study into practical assay designs, controls, and troubleshooting decisions.
-
InstaBlue Protein Stain Solution Protocol
2026-08-31
InstaBlue Protein Stain Solution provides rapid Coomassie-based visualization of protein bands in polyacrylamide gels without fixation, washing, or destaining. It is suited to routine protein electrophoresis analysis and samples intended for mass spectrometry, but compatibility with non-polyacrylamide matrices and long-term archival staining should be validated separately.
-
Mithramycin A Workflows for Cancer Research
2026-08-31
Mithramycin A combines G-C-rich DNA recognition with transcription-focused assay design, making it useful for c-myc studies, myeloid differentiation experiments, and promoter-level mechanistic work. This guide translates its chemistry into practical workflows while showing how findings from a doxorubicin-induced heart-failure study can inform—not replace—cancer biology experiments.
-
U 46619 in Platelet and Vascular Research
2026-08-30
U 46619 provides a controllable TP-receptor stimulus for separating platelet shape change, signaling, serotonin release, aggregation, and vascular tone. This guide translates its concentration-dependent biology into practical assay workflows, endpoint selection, and troubleshooting strategies for cardiovascular and renal research.
-
Sulfamonomethoxine: From Use to Environmental Fate
2026-08-29
Sulfamonomethoxine (SMM) is examined through a decision-focused framework linking DHPS inhibition, veterinary and aquaculture use, assay formulation, and environmental transformation. Drawing on aerobic granular sludge research, this guide shows how to distinguish adsorption from biodegradation and interpret aquatic toxicity responsibly.
-
Psora 4: Kv1.3 Blocker Workflows
2026-08-29
Psora 4 enables mechanism-focused studies of Kv1.3-dependent T-cell signaling, from acute calcium imaging to effector-memory proliferation assays. Its value is greatest when concentration, solvent, cell phenotype, and KCNE4-dependent channel architecture are controlled together.
-
CSBTA Pharmacokinetics in MASH: Key Study Insights
2026-08-28
A 2025 study integrated pharmacokinetic, tissue-distribution, transport, and metabolism data to show how HFHCD-induced MASH changes the disposition of Corydalis saxicola Bunting total alkaloids. Its findings indicate that disease state and repeated dosing can increase systemic exposure, hepatic distribution, and hepatocyte accumulation through coordinated changes in CYP450 enzymes and transporters regulated in part through PXR.
-
ROS-Driven Metabolic Rewiring in Melanoma
2026-08-28
Cesi et al. show that BRAF or MEK pathway inhibition increases reactive oxygen species, activates pyruvate dehydrogenase kinases, and phosphorylates PDH-E1α in melanoma cells. The study identifies PDK inhibition as a potential metabolic vulnerability, including in BRAF inhibitor-resistant models, while highlighting the need to control metabolic variables in cell-culture experiments.